Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of LW231 in Healthy Volunteers and Chronic Hepatitis B
NCT06311734Phase 1Completed
- Sponsor
- Shanghai Longwood Biopharmaceuticals Co., Ltd.
- Start
- Jun 2022
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LW231 in Chronic Hepatitis B (CHB) (3 arms), sponsored by Shanghai Longwood Biopharmaceuticals Co., Ltd. Primary endpoint: Number of Participants With Adverse Events (AEs). Started Jun 2022; status: completed.
02
Drugs
LW231
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06311734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06311734.